The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1428
October 28, 2013
View Complete Issue         Table of Contents 2019 
Topiramate Extended-Release (Trokendi XR) for Epilepsy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Topiramate Extended-Release (Trokendi XR) for Epilepsy
October 28, 2013 (Issue: 1428)
The FDA has approved a once-daily extended-release (ER) formulation of the antiepileptic topiramate (Trokendi XR – Supernus) for initial monotherapy in patients ≥10 years old with partial onset seizures or primary generalized tonic-clonic...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Topiramate Extended-Release (Trokendi XR) for Epilepsy
Article code: 1428c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.